nifedipine has been researched along with erythromycin in 44 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (31.82) | 18.2507 |
| 2000's | 15 (34.09) | 29.6817 |
| 2010's | 15 (34.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belas, F; Chaudhary, AK; Cvetkovic, M; Dempsey, PJ; Fromm, MF; Kim, RB; Leake, B; Roden, DM; Roden, MM; Wandel, C; Wilkinson, GR; Wood, AJ | 1 |
| Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
| Johans, C; Kinnunen, PK; Söderlund, T; Suomalainen, P | 1 |
| Du, LP; Li, MY; Tsai, KC; Xia, L; You, QD | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Pratim Roy, P; Roy, K | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Beaumont, K; Di, L; Maurer, TS; Smith, DA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Farrugia, G; Rae, JL; Rich, A; Sarr, MG; Szurszewski, JH | 1 |
| el-Tahtawy, AA; Jackson, AJ; Ludden, TM | 1 |
| Buters, JT; Friedman, FK; Koley, AP; Markowitz, A; Robinson, RC | 1 |
| Ring, BJ; Wrighton, SA | 1 |
| Watkins, PB | 1 |
| Estabrook, RW; Fisher, CW; Holmans, PL; Shet, MS | 1 |
| Hiroki, S; Shimada, T; Urano, T; Yamazaki, H | 1 |
| Costa, A; Crema, F; d'Angelo, L; De Ponti, F; Gibelli, G | 1 |
| Arimori, K; Nakamura, K; Nakano, M; Tsuruta, S | 2 |
| Inoue, K; Mimura, M; Nakamura, S; Oda, H; Ohmori, S; Shimada, T; Yamazaki, H | 1 |
| Ishizaki, T; Zhao, XJ | 1 |
| Ball, SE; Ferron, GM; Fruncillo, R; Guida, M; Hall, J; Hopkins, PJ; Kao, J; Mayer, P; Scatina, J; Warner, N; Weinryb, I | 1 |
| Fowler, SM; Friedberg, T; Pritchard, MP; Riley, RJ; Sutcliffe, MJ; Wolf, CR | 1 |
| Emoto, C; Iketaki, H; Nakajima, M; Satoh, T; Shimada, N; Shimizu, R; Suzuki, S; Yamasaki, S; Yamazaki, H; Yokoi, T | 1 |
| Bae, KS; Cho, JY; Jang, IJ; Lim, HS; Shin, SG; Shon, JH; Yi, SY; Yu, KS | 1 |
| Bennett, PR; Terzidou, V | 1 |
| Farkas, S; Gunics, G; Harsukh, G; Kawase, M; Molnár, J; Motohashi, N; Shah, A | 1 |
| Elliott, RA; England, RC; Norman, RI | 1 |
| Abenhaim, HA; Gangal, M; Xiao, C | 1 |
| Akiyoshi, T; Imaoka, A; Ishikawa, Y; Ohtani, H | 1 |
3 review(s) available for nifedipine and erythromycin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Noninvasive tests of CYP3A enzymes.
Topics: Animals; Breath Tests; Cytochrome P-450 Enzyme System; Dapsone; Erythromycin; Humans; Hydrocortisone; Lidocaine; Liver; Midazolam; Nifedipine | 1994 |
Preterm labour.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Cerclage, Cervical; Cervix Uteri; Erythromycin; Female; Fibronectins; Genetic Predisposition to Disease; Glycoproteins; Humans; Inflammation Mediators; Nifedipine; Obstetric Labor, Premature; Predictive Value of Tests; Pregnancy; Randomized Controlled Trials as Topic; Tocolytic Agents; Ultrasonography | 2002 |
2 trial(s) available for nifedipine and erythromycin
| Article | Year |
|---|---|
Comparison of single and multiple dose pharmacokinetics using clinical bioequivalence data and Monte Carlo simulations.
Topics: Adolescent; Adult; Cross-Over Studies; Erythromycin; Humans; Indomethacin; Male; Middle Aged; Monte Carlo Method; Nifedipine; Procainamide; Quinidine; Therapeutic Equivalency | 1994 |
Ethnic differences and relationships in the oral pharmacokinetics of nifedipine and erythromycin.
Topics: Adult; Anti-Bacterial Agents; Area Under Curve; Asian People; Body Weight; Calcium Channel Blockers; Cross-Over Studies; Double-Blind Method; Erythromycin; Humans; Intestinal Absorption; Male; Nifedipine; Tablets, Enteric-Coated; White People | 2001 |
39 other study(ies) available for nifedipine and erythromycin
| Article | Year |
|---|---|
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Resistance, Multiple; Enzyme Inhibitors; Humans; Male; Mice; Oxidoreductases, N-Demethylating; Pharmacokinetics; Substrate Specificity | 1999 |
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
Topics: Blood-Brain Barrier; Lipid Bilayers; Micelles; Permeability; Pharmaceutical Preparations; Structure-Activity Relationship; Surface Properties | 2004 |
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
Topics: Anti-Arrhythmia Agents; Models, Biological; Models, Molecular; Potassium Channel Blockers; Potassium Channels; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.
Topics: Algorithms; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Enzyme Inhibitors; Factor Analysis, Statistical; Least-Squares Analysis; Linear Models; Models, Molecular; Neural Networks, Computer; Quantitative Structure-Activity Relationship; Reproducibility of Results | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Volume of Distribution in Drug Design.
Topics: Drug Design; Half-Life; Pharmacokinetics | 2015 |
Calcium currents in human and canine jejunal circular smooth muscle cells.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Acetylcholine; Animals; Calcium Channels; Diltiazem; Dogs; Erythromycin; Humans; In Vitro Techniques; Jejunum; Membrane Potentials; Muscle, Smooth; Nifedipine; Patch-Clamp Techniques | 1995 |
CO binding kinetics of human cytochrome P450 3A4. Specific interaction of substrates with kinetically distinguishable conformers.
Topics: Animals; Carbon Monoxide; Cimetidine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Erythromycin; Ethinyl Estradiol; Humans; Kinetics; Mixed Function Oxygenases; Nifedipine; Protein Binding; Quinidine; Recombinant Proteins; Spodoptera; Substrate Specificity; Testosterone; Time Factors; Transfection; Warfarin | 1995 |
Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine.
Topics: Chromatography, High Pressure Liquid; Cimetidine; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Erythromycin; Humans; In Vitro Techniques; Ketoconazole; Microsomes, Liver; Midazolam; Nifedipine; Nizatidine | 1994 |
Human cytochrome P450 3A4: enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase.
Topics: Base Sequence; Cloning, Molecular; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Cytochromes b5; DNA Primers; Erythromycin; Escherichia coli; Humans; Hydroxylation; Kinetics; Liver; Mixed Function Oxygenases; Molecular Sequence Data; Mutagenesis; NADPH-Ferrihemoprotein Reductase; Nifedipine; Plasmids; Polymerase Chain Reaction; Recombinant Fusion Proteins; Substrate Specificity; Testosterone | 1993 |
Effects of erythromycin and roxithromycin on oxidation of testosterone and nifedipine catalyzed by CYP3A4 in human liver microsomes.
Topics: Animals; Anti-Bacterial Agents; Catalysis; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Erythromycin; Humans; Ketoconazole; Male; Microsomes, Liver; Mixed Function Oxygenases; Nifedipine; Oxidation-Reduction; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Roxithromycin; Testosterone; Troleandomycin | 1996 |
In vivo characterization of the colonic prokinetic effect of erythromycin in the rabbit.
Topics: Animals; Anti-Bacterial Agents; Atropine; Calcium Channel Blockers; Colon; Dose-Response Relationship, Drug; Electrodes, Implanted; Erythromycin; Female; Gastrointestinal Motility; In Vitro Techniques; Male; Muscarinic Antagonists; Nifedipine; Ondansetron; Rabbits; Serotonin Antagonists; Stimulation, Chemical | 1997 |
Effects of erythromycin, clarithromycin and rokitamycin on nifedipine metabolism in rats.
Topics: Animals; Anti-Bacterial Agents; Calcium Channel Blockers; Clarithromycin; Drug Interactions; Erythromycin; In Vitro Techniques; Intestinal Absorption; Jugular Veins; Male; Microsomes, Liver; Miocamycin; Nifedipine; Portal Vein; Rats; Rats, Wistar | 1997 |
Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans.
Topics: Adrenergic beta-Antagonists; Aniline Compounds; Animals; Antineoplastic Agents; Benzphetamine; Carcinogens; Coumarins; Cytochrome P-450 Enzyme System; Dogs; Erythromycin; Ethanolamines; Ethylmorphine; Guinea Pigs; Humans; Macaca fascicularis; Mephenytoin; Microsomes, Liver; Nifedipine; Oxazines; Oxidation-Reduction; Phenacetin; Phenytoin; Rats; Species Specificity | 1997 |
Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes.
Topics: Anti-Infective Agents; Antimalarials; Chromatography; Cytochrome P-450 Enzyme System; Doxycycline; Drug Interactions; Erythromycin; Humans; Hydroxylation; Ketoconazole; Microsomes, Liver; Nifedipine; Omeprazole; Primaquine; Quinine; Tetracycline; Troleandomycin | 1997 |
Inhibition of nifedipine metabolism in dogs by erythromycin: difference between the gut wall and the liver.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biological Availability; Calcium Channel Blockers; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dogs; Drug Interactions; Erythromycin; In Vitro Techniques; Intestine, Small; Kinetics; Liver; Male; Microsomes; Miocamycin; Nifedipine; Oxidoreductases, N-Demethylating; Portal Vein; Rats; Rats, Wistar | 1997 |
Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4.
Topics: Area Under Curve; Asian People; Black People; Breath Tests; Calcium Channel Blockers; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; DNA Primers; Erythromycin; Genotype; Hispanic or Latino; Humans; Mixed Function Oxygenases; Nifedipine; Phenotype; Polymorphism, Genetic; Promoter Regions, Genetic; Protein Synthesis Inhibitors; Racial Groups; Reference Values; White People | 1999 |
Amino acid 305 determines catalytic center accessibility in CYP3A4.
Topics: Alanine; Amino Acid Substitution; Aryl Hydrocarbon Hydroxylases; Binding Sites; Catalysis; Clotrimazole; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diazepam; Econazole; Erythromycin; Humans; Imidazoles; Ketoconazole; Kinetics; Miconazole; Mixed Function Oxygenases; Multienzyme Complexes; Mutation; Nifedipine; Oxidoreductases, N-Demethylating; Substrate Specificity; Testosterone | 2000 |
Cooperativity of alpha-naphthoflavone in cytochrome P450 3A-dependent drug oxidation activities in hepatic and intestinal microsomes from mouse and human.
Topics: Animals; Benzoflavones; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Enzyme Inhibitors; Erythromycin; GABA Modulators; Gastrointestinal Agents; Histamine H1 Antagonists; Humans; Inhibitory Concentration 50; Intestines; Kinetics; Mice; Microsomes; Microsomes, Liver; Midazolam; Mixed Function Oxygenases; Nifedipine; Oxygen; Protein Binding; Steroid Hydroxylases; Terfenadine; Testosterone; Vasodilator Agents | 2001 |
Interaction between 3,5-diacetyl-1,4-dihydropyridines and ampicillin, and erythromycin on different E. coli strains.
Topics: Ampicillin; Anti-Bacterial Agents; Dihydropyridines; Drug Interactions; Drug Resistance, Bacterial; Erythromycin; Escherichia coli; Microbial Sensitivity Tests; Molecular Structure; Nifedipine | 2002 |
Direct inhibition of rat detrusor muscle contraction by erythromycin.
Topics: Adenosine Triphosphate; Animals; Anti-Bacterial Agents; Atropine; Calcium Channel Blockers; Calcium Signaling; Carbachol; Central Nervous System Depressants; Erythromycin; Ethanol; In Vitro Techniques; Muscarinic Agonists; Muscarinic Antagonists; Muscle Contraction; Muscle, Smooth; Nifedipine; Potassium; Rats; Rats, Wistar; Urinary Bladder | 2004 |
Effect of magnesium sulfate and nifedipine on the risk of developing pulmonary edema in preterm births.
Topics: Adult; Azithromycin; Case-Control Studies; Drug Synergism; Erythromycin; Female; Humans; Infant, Newborn; Logistic Models; Magnesium Sulfate; Nifedipine; Obstetric Labor, Premature; Pregnancy; Pregnancy Complications; Pregnancy, Multiple; Premature Birth; Pulmonary Edema; Retrospective Studies; Risk Factors; Tocolysis; Tocolytic Agents; Young Adult | 2014 |
Inactivation kinetics and residual activity of CYP3A4 after treatment with erythromycin.
Topics: Anti-Bacterial Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Erythromycin; Kinetics; Midazolam; Nifedipine; Testosterone | 2017 |